FDA decisions and public deliberation: Challenges and opportunities

Public Administration Review

Volumn 73, Issue SUPPL.1, 2013, Pages

  Gusmano, Michael K ^a  

^a HASTINGS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884355810     PISSN: 00333352     EISSN: 15406210     Source Type: Journal    
DOI: 10.1111/puar.12121     Document Type: Article

References (72)

1. Abelson, Julia, Mita Giacomini, Pascale Lehoux, and François-Pierre Gauvin 2007. Bringing "the Public" into Health Technology Assessment and Coverage Policy Decisions: From Principles to Practice. Health Policy 82(1): 37-50.
2. Ackerley, Nyssa, John Eyraud, and Marisa Mazzotta 2007. Measuring Conflict of Interest and Expertise on FDA Advisory Committees. Report submitted to the Office of Policy, Planning and Preparedness, U.S. Food and Drug Administration, October 26. http://www.fda.gov/oc/advisory/ergcoireport.pdf [accessed July 24, 2013].
3. Arcia, Adriana. 2012. Accessing Hidden Populations: Advertisements on Social Networking Websites for Cost-Effective Participant Recruitment. Paper presented at the American Public Health Association Meeting, San Francisco, October 31.
4. Aristotle. 1912. Politics: A Treatise on Government. Trans. William Ellis. London: J. M. Dent & Sons.
5. Berry, Jeffrey M., with David F. Arons 2003. A Voice for Nonprofits. Washington, DC: Brookings Institution Press.
6. Blacksher, Erika, Alice Diebel, Pierre-Gerlier Forest, Susan Dorr Goold, and Julia Abelson 2012. What Is Public Deliberation? Hastings Center Report 42(2): 14-17.
7. Carpenter, Daniel. 2002. Groups, the Media, Agency Waiting Costs, and FDA Drug Approval. American Journal of Political Science 46(3): 490-505.
8. Carpenter, Daniel. 2010. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press.
9. Carpenter, Daniel, Jacqueline Chattopadhyay, Susan Moffitt, and Clayton Nall 2012. The Complications of Controlling Agency Time Discretion: FDA Review Deadlines and Postmarket Drug Safety. American Journal of Political Science 56(1): 98-114.
10. Carpenter, Daniel, Evan J. Zucker, and Jerry Avorn 2008. Drug Review Deadlines and Safety Problems. New England Journal of Medicine 358(13): 1354-61.
11. Carpini, Michael X. Delli, Fay Lomax Cook, and Lawrence R. Jacobs. 2004. Public Deliberation, Discursive Participation, and Citizen Engagement: A Review of the Empirical Literature. Annual Review of Political Science 7: 315-44.
12. Chung, Phillip, Colleen M. Grogan, and Jennifer E. Mosley 2010. Residents' Perceptions of Effective Community Representation in Local Health Decision-Making. Paper presented at the Public Deliberation, Ethics and Health Policy Symposium, Ann Arbor, MI, September 11.
13. Davis, Courtney, and John Abraham 2011. Desperately Seeking Cancer Drugs: Explaining the Emergence and Outcomes of Accelerated Pharmaceutical Regulation. Sociology of Health and Illness 33(5): 731-47.
14. Dresser, Rebecca. 2001. Patient Advocates in Research: New Possibilities, New Problems. Address presented at installation ceremony, Washington University in St. Louis, November 16.
15. Dryzek, John S. 2011. Global Democratization: Soup, Society, or System? Ethics and International Affairs 25(2): 211-34.
16. Dubois, Vincent. 2010. The Bureaucrat and the Poor: Encounters in French Welfare Offices. Trans. Jean-Yves Bart. Burlington, VT: Ashgate.
17. Epstein, Steven. 2007. Inclusion: The Politics of Difference in Medical Research. Chicago: University of Chicago Press.
18. Fearon, James D. 1998. Deliberation as Discussion. In Deliberative Democracy, edited by John Elster, 19-43. New York: Cambridge University Press.
19. Fenner, Yeshe, Suzanne M. Garland, Elya E. Moore, Yasmin Jayasinghe, Ashley Fletcher, Sepehr N. Tabrizi, Bharathy Gunasekaran, and John D. Wark 2012. Web-Based Recruiting for Health Research Using a Social Networking Site: An Exploratory Study. Journal of Medical Internet Research 14(1): e20. http://www.jmir.org/2012/1/e20/ [accessed July 24, 2013].
20. Foreman, Judy. 2012. Pain Foundation's Drug Money Was a Shame, but So Is Group's Demise. CommonHealth, May 9. http://commonhealth.wbur.org/2012/05/judy-foreman-pain-foundation [accessed July 24, 2013].
21. Gambetta, Diego. 1998. Claro! An Essay on Discursive Machismo. In Deliberative Democracy, edited by John Elster, 19-43. New York: Cambridge University Press.
22. Gauvin, François-Pierre, Julia Abelson, Mita Giacomini, John Eyles, and John N. Lavis 2011. Moving Cautiously: Public Involvement and the Health Technology Assessment Community. International Journal of Technology Assessment in Health Care 27(1): 43-49.
23. Grob, Rachel. 2011. Testing Baby: The Transformation of Newborn Screening, Parenting, and Policymaking. New Brunswick, NJ: Rutgers University Press.
24. Grogan, Colleen M., and Michael K. Gusmano 2007. Health Voices/Unhealthy Silence: Advocacy and Health Policy for the Poor. Washington, DC: Georgetown University Press.
25. Gusmano, Michael K., and Bradford H. Gray 2010. Evidence and Fear: Navigating the Politics of Evidence Based Medicine. AcademyHealth Reports, June 1. http://www.academyhealth.org/evidenceandfear [accessed July 24, 2013].
26. Gutmann, Amy, and Dennis Thompson 1996. Democracy and Disagreement: Why Moral Conflict Cannot Be Avoided in Politics, and What Should Be Done about It. Cambridge, MA: Harvard University Press.
27. Gutmann, Amy, and Dennis Thompson 1999. Democratic Disagreement. In Deliberative Politics: Essays on Democracy and Disagreement, edited by Stephen Macedo, 243-79. New York: Oxford University Press.
28. Habermas, Jürgen. 1984. The Theory of Communicative Action. Vol. 1. Boston: Beacon Press.
29. Habermas, Jürgen. 1987. The Theory of Communicative Action. Vol. 2. Boston: Beacon Press.
30. Habermas, Jürgen, and William Rehg 1996. Between Facts and Norms: Contributions to a Discourse Theory of Law and Democracy. Cambridge, MA: MIT Press.
31. Hoffman, Beatrice. 2003. Health Care Reform and Social Movements in the United States. American Journal of Public Health 93(1): 75-85.
32. Karpowitz, Christopher F., Tali Mendelberg, and Lee Shaker 2012. Gender Inequality in Deliberative Participation. American Political Science Review 106(3): 533-47.
33. King & Spalding. 2012. FDA Issues Final Guidance on Factors to Consider When Making Benefit-Risk Determinations in Premarket Approval and De Novo Classifications. King & Spalding Client Alert, April 25. http://www.kslaw.com/imageserver/KSPublic/library/publication/ca042512.pdf [accessed July 24, 2013].
34. Lavertu, Stéphane, and David L. Weimer 2001. Federal Advisory Committees, Policy Expertise, and the Approval of Drugs and Medical Devices at the FDA. Journal of Public Administration Research and Theory 21(2): 211-37.
35. Lindblom, Charles E. 1965. The Intelligence of Democracy: Decision Making through Mutual Adjustment. New York: Free Press.
36. Long, Norton E. 1962. The Polity. Chicago: Rand McNally.
37. Lurie, Peter, Cristina M. Almeida, Nicholas Stine, Alexander R. Stine, and Sidney M. Wolfe 2006. Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings. Journal of the American Medical Association 295(16): 1921-28.
38. Mansbridge, Jane. 1980. Beyond Adversary Democracy. New York: Basic Books.
39. Maor, Moshe, and Raanan Sulitzeanu-Kenan 2013. The Effect of Salient Reputational Threats on the Pace of FDA Enforcement. Governance 26(1): 31-61.
40. McCain, Jack. 2011. Doing More with Less? Past and Present Challenges for the FDA. Pharmacy and Therapeutics 36(3): 145-55.
41. Miller, Henry I. 2010. The FDA's Imprudent Caution. Policy Review, no. 161: 73-85.
42. Moffitt, Susan L. 2010. Promoting Agency Reputation through Public Advice: Advisory Committee Use in the FDA. Journal of Politics 72(3): 880-93.
43. Morone, James A. 1990. The Democratic Wish: Popular Participation and the Limits of American Government. New York: Basic Books.
44. Mosher, Frederick C. 1982. Democracy and the Public Service. New York: Oxford University Press
45. Moynihan, Ray, and Alan Cassels 2005. Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. New York: Nation Books.
46. Nabatchi, Tina. 2010. Addressing the Citizenship and Democratic Deficits: The Potential of Deliberative Democracy for Public Administration. American Review of Public Administration 40(4): 376-99.
47. Nagler, Rebekah H., Elaine Puleo, Kim Sprunck-Harrild, and Karen M. Emmons 2012. Internet Use among Childhood and Young Adult Cancer Survivors Who Smoke: Implications for Cessation Interventions. Cancer Causes and Control 23(4): 647-52.
48. Neblo, Michael A., Kevin M. Esterling, Ryan P. Kennedy, David M. J. Lazer, Anand E. Sokhey. 2010. Who Wants to Deliberate-And Why? American Political Science Review 104(3): 566-83.
49. O'Doherty, Kieran, François-Pierre Gauvin, Colleen Grogan, and Will Friedman 2012. Implementing a Public Deliberative Forum. Hastings Center Report 42(2): 20-23.
50. Ornstein, Charles, and Tracy Weber 2012. American Pain Foundation Shuts Down as Senators Launch Investigation of Prescription Narcotics. ProPublica: Journalism in the Public Interest, May 8. http://www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups [accessed July 24, 2013].
51. Pateman, Carole. 2012. Participatory Democracy Revisited: APSA Presidential Address. Perspectives on Politics 10(1): 7-19.
52. Qato, Dima M., and G. Caleb Alexander 2011. Improving the Food and Drug Administration's Mandate to Ensure Postmarketing Drug Safety. Journal of the American Medical Association 306(14): 1595-96.
53. Roberts, Samantha A., Jeff D. Allen, and Ellen V. Sigal 2011. Despite Criticism of the FDA Review Process, New Cancer Drugs Reach Patients Sooner in the United States than Europe. Health Affairs 30(7): 1375-81.
54. Rodwin, Marc A., and John D. Abramson 2012. Clinical Trial Data as a Public Good. Journal of the American Medical Association 308(9): 871-72.
55. Roth, Duane. 2011. A Third Seat at the Table: An Insider's Perspective on Patient Representatives. Hastings Center Report 41(1): 29-31.
56. Rothman, Sheila M., Victoria H. Raveis, Anne Friedman, David J. Rothman 2011. Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices. American Journal of Public Health 101(4): 602-9.
57. Ruzek, Sheryl B., and Julie Becker 1999. The Women's Health Movement in the United States: From Grass-Roots Activism to Professional Agendas. Journal of the American Medical Women's Association 54(1): 4-8, 40.
58. Simon, William H. 1999. Three Limitations of Deliberative Democracy: Identity Politics, Bad Faith, and Indeterminacy. In Deliberative Politics: Essays on Democracy and Disagreement, edited by Stephen Macedo and Cass R. Sunstein, 49-57. New York: Oxford University Press.
59. Solomon, Stephanie, and Julia Abelson 2012. Why and When Should We Use Public Deliberation? Hastings Center Report 42(2): 17-19.
60. Staszewski, Glen. 2012. Political Reasons, Deliberative Democracy, and Administrative Law. Iowa Law Review 97(3): 849-912.
61. Sunstein, Cass R. 2003. Why Societies Need Dissent. Cambridge, MA: Harvard University Press.
62. Taylor, Frederick Winslow. 1967. The Principles of Scientific Management. New York: W. W. Norton.
63. U.S. Food and Drug Administration (FDA). 2012a. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2013 through 2017. http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf. [accessed July 24, 2013].
64. U.S. Food and Drug Administration (FDA). 2012b. Patient Representatives to FDA Advisory Committees. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/PatientInvolvement/ucm123861.htm [accessed July 24, 2013].
65. U.S. Food and Drug Administration (FDA). 2013. Prescription Drug User Fee Act. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm272170.htm [accessed July 24, 2013].
66. Waldo, Dwight. 1948. The Administrative State: A Study of the Political Theory of American Public Administration. New York: Ronald Press.
67. Waldo, Dwight. 1980. The Enterprise of Public Administration. Novato, CA: Chandler & Sharp.
68. Walzer, Michael. 1983. Spheres of Justice: A Defense of Pluralism and Equality. New York: Basic Books.
69. Wechsler, Jill. 2012. FDA User Fee Renewal Addresses Drug Shortages, New Drug Development. Formulary 47: 125-26.
70. Wilson, Woodrow. 1887. The Study of Administration. Political Science Quarterly 2(2): 197-222.
71. Young, Iris Marion. 2000. Inclusion and Democracy. New York: Oxford University Press.
72. Zamosky, Lisa. 2012. Social Media Offers New Recruitment Strategy for Clinical Trials. iHealthBeat: Reporting Technologies Impact on Health Care, March 1. http://www.ihealthbeat.org/features/2012/social-media-offers-new-recruitment-strategy-for-clinical-trials.aspx [accessed July 24, 2013].